Question to the Department for Business and Trade:

To ask the Secretary of State for Business and Trade, what mechanisms within the UK-US Economic Prosperity Deal will ensure that pharmaceutical products launched in the UK with a lower price than in the US will not trigger Most Favoured Nation rebates.

We have secured the first and only deal with the US that delivers zero percent tariffs on pharmaceutical products – the lowest rate offered to any country.

It delivers mitigations on the US’ ‘Most Favoured Nation’ policy and preferential terms for UK medtech exports – helping expand access to innovative treatments for patients and driving crucial investment in the UK.

The UK and the US have confirmed the headline terms of this deal. Further work to finalise underpinning details is ongoing.